Anteris Technologies Global Corp. AVR 深 滬
已收盤 01-09 16:00:00 美东时间
4.55
-0.290
-5.99%
華盛通- 最 高4.93
- 今 開4.75
- 成交量 21.93万股
- 最 低 4.54
- 昨 收 4.84
- 總市值 1.87亿
- 52周最高 8.79
- 市盈率 靜 --
- 換手率 0.53%
- 52周最低 2.34
- 委 比 56.32%
- 總股本 4119.76万
- 歷史最高 8.79
- 量 比 1.30
- 振 幅 8.06%
- 歷史最低 2.34
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anteris Technologies Shifts More CDIs Into Nasdaq-Listed Common Stock
Anteris Technologies ( ($AU:AVR) ) has shared an announcement. Anteris Technolo...
01-08 12:24
Anteris Technologies Announces Lapse of Equity Securities
Anteris Technologies ( ($AU:AVR) ) has issued an announcement. Anteris Technolo...
01-05 07:17
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
2025-12-19 01:06
Stephen Denaro Resigns from Anteris Board
Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On Decemb...
2025-12-15 19:29
Anteris Technologies Issues Restricted Stock Units
Anteris Technologies ( ($AU:AVR) ) has shared an update. Anteris Technologies G...
2025-12-12 14:18
Anteris Technologies Reports Q3 2025 Progress and Financials
Anteris Technologies Global Corp. ( ($AVR) ) has released its Q3 earnings. Here...
2025-11-24 11:50
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Anteris Technologies Global Corp. announced 30-day clinical outcomes for the DurAVR® THV in 100 severe aortic stenosis patients with small aortic annuli. The device showed favorable hemodynamic performance, including low pressure gradients, reduced prosthesis-patient mismatch (PPM), and no moderate or severe paravalvular leaks. With a 97% freedom from moderate or severe PPM and 100% technical success rate in the last 50 implants, the DurAVR® THV ...
2025-11-17 11:00
Anteris Announces Results for the Third Quarter of 2025
Anteris reported Q3 2025 financial results, highlighting FDA and European approvals for the PARADIGM Trial, patient recruitment progress, operational readiness enhancements, and $59.3 million net cash outflow. Key focus areas included regulatory advancement, clinical trial preparation, and manufacturing scale-up.
2025-11-12 22:52
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Anteris Technologies Global Corp. announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in patients with symptomatic severe aortic stenosis and small aortic annuli. The DurAVR® system demonstrated favorable hemodynamics, including an effective orifice area (EOA) of 2.1 ± 0.2 cm² and a mean pressure gradient (MPG) of 8.6 ± 2.6 mmHg, with no moderate or severe paravalvular leaks or valve-related mortality. At 30 days,...
2025-10-28 22:08
Anteris Technologies Requests Voluntary Suspension of Securities
The latest update is out from Anteris Technologies ( ($AU:AVR) ). Anteris Techn...
2025-10-28 10:18
